Novavax Statistics
Total Valuation
Novavax has a market cap or net worth of $1.56 billion. The enterprise value is $1.17 billion.
Important Dates
The next estimated earnings date is Thursday, May 7, 2026, before market open.
| Earnings Date | May 7, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Novavax has 162.94 million shares outstanding. The number of shares has increased by 13.74% in one year.
| Current Share Class | 162.94M |
| Shares Outstanding | 162.94M |
| Shares Change (YoY) | +13.74% |
| Shares Change (QoQ) | +1.74% |
| Owned by Insiders (%) | 0.62% |
| Owned by Institutions (%) | 59.27% |
| Float | 140.48M |
Valuation Ratios
The trailing PE ratio is 3.72.
| PE Ratio | 3.72 |
| Forward PE | n/a |
| PS Ratio | 1.45 |
| Forward PS | 3.76 |
| PB Ratio | n/a |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | 2.67 |
| EV / Sales | 1.04 |
| EV / EBITDA | 1.99 |
| EV / EBIT | 2.08 |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 2.13
| Current Ratio | 2.13 |
| Quick Ratio | 1.83 |
| Debt / Equity | n/a |
| Debt / EBITDA | 0.46 |
| Debt / FCF | n/a |
| Interest Coverage | 24.98 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | 25.72% |
| Return on Invested Capital (ROIC) | n/a |
| Return on Capital Employed (ROCE) | 78.60% |
| Weighted Average Cost of Capital (WACC) | 17.17% |
| Revenue Per Employee | $1.50M |
| Profits Per Employee | $587,853 |
| Employee Count | 749 |
| Asset Turnover | 0.82 |
| Inventory Turnover | 40.39 |
Taxes
In the past 12 months, Novavax has paid $1.87 million in taxes.
| Income Tax | 1.87M |
| Effective Tax Rate | 0.42% |
Stock Price Statistics
The stock price has increased by +19.45% in the last 52 weeks. The beta is 2.63, so Novavax's price volatility has been higher than the market average.
| Beta (5Y) | 2.63 |
| 52-Week Price Change | +19.45% |
| 50-Day Moving Average | 9.15 |
| 200-Day Moving Average | 7.94 |
| Relative Strength Index (RSI) | 52.59 |
| Average Volume (20 Days) | 5,406,192 |
Short Selling Information
The latest short interest is 50.92 million, so 31.25% of the outstanding shares have been sold short.
| Short Interest | 50.92M |
| Short Previous Month | 50.85M |
| Short % of Shares Out | 31.25% |
| Short % of Float | 36.25% |
| Short Ratio (days to cover) | 10.16 |
Income Statement
In the last 12 months, Novavax had revenue of $1.12 billion and earned $440.30 million in profits. Earnings per share was $2.58.
| Revenue | 1.12B |
| Gross Profit | 713.62M |
| Operating Income | 563.24M |
| Pretax Income | 442.17M |
| Net Income | 440.30M |
| EBITDA | 590.85M |
| EBIT | 563.24M |
| Earnings Per Share (EPS) | $2.58 |
Full Income StatementBalance Sheet
The company has $735.08 million in cash and $278.05 million in debt, with a net cash position of $457.04 million or $2.81 per share.
| Cash & Cash Equivalents | 735.08M |
| Total Debt | 278.05M |
| Net Cash | 457.04M |
| Net Cash Per Share | $2.81 |
| Equity (Book Value) | -127.75M |
| Book Value Per Share | -0.79 |
| Working Capital | 518.33M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$244.64 million and capital expenditures -$5.56 million, giving a free cash flow of -$250.20 million.
| Operating Cash Flow | -244.64M |
| Capital Expenditures | -5.56M |
| Free Cash Flow | -250.20M |
| FCF Per Share | -$1.54 |
Full Cash Flow StatementMargins
Gross margin is 63.52%, with operating and profit margins of 50.13% and 39.19%.
| Gross Margin | 63.52% |
| Operating Margin | 50.13% |
| Pretax Margin | 39.36% |
| Profit Margin | 39.19% |
| EBITDA Margin | 52.59% |
| EBIT Margin | 50.13% |
| FCF Margin | n/a |
Dividends & Yields
Novavax does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -13.74% |
| Shareholder Yield | -13.74% |
| Earnings Yield | 27.00% |
| FCF Yield | -15.34% |
Analyst Forecast
The average price target for Novavax is $11.33, which is 18.39% higher than the current price. The consensus rating is "Hold".
| Price Target | $11.33 |
| Price Target Difference | 18.39% |
| Analyst Consensus | Hold |
| Analyst Count | 9 |
| Revenue Growth Forecast (5Y) | -16.62% |
| EPS Growth Forecast (5Y) | -27.38% |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on May 10, 2019. It was a reverse split with a ratio of 1:20.
| Last Split Date | May 10, 2019 |
| Split Type | Reverse |
| Split Ratio | 1:20 |
Scores
Novavax has an Altman Z-Score of -1.81 and a Piotroski F-Score of 5. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -1.81 |
| Piotroski F-Score | 5 |
